Table 3 Association of anthropometric measures and MetS with all-cause and BC-specific mortality by molecular subtypes, Naples, Italy, 2009–2022.

From: Central obesity, body mass index, metabolic syndrome and mortality in Mediterranean breast cancer patients

 

HR+

HER 2+

TN

Deaths from all-causes

Deaths from breast cancer

Deaths from all-causes

Deaths from breast cancer

Deaths from all-causes

Deaths from breast cancer

HR* (95% CI)

p**

HR* (95% CI)

p**

HR* (95% CI)

p**

HR* (95% CI)

p**

HR* (95% CI)

p**

HR* (95% CI)

p**

Body mass index, kg/m2

 

0.433

 

0.087

 

0.501

 

0.183

 

0.835

 

0.855

 < 25

1

 

1

 

1

 

1

 

1

 

1

 

 25–30

1.10 (0.68–1.78)

 

1.03 (0.53–1.99)

 

0.93 (0.36–2.42)

 

1.03 (0.29–3.61)

 

0.76 (0.26–2.17)

 

1.25 (0.38 –4.04)

 

 ≥ 30

1.35 (0.82–2.21)

 

1.78 (0.94–3.37)

 

1.53 (0.64–3.68)

 

2.47 (0.84–7.27)

 

0.77 (0.28–2.15)

 

0.88 (0.25–3.12)

 

 Per 5 U

1.21 (1.01–1.44)

0.035

1.58 (1.11–1.72)

0.004

1.23 (0.89–1.68)

0.207

1.42 (0.94–2.16)

0.096

1.11 (0.75–1.14)

0.616

1.16 (0.74–1.84)

0.519

Waist circumference, cm

 

0.088

 

0.052

 

0.245

 

0.087

 

0.999

 

0.993

 < 88

1

 

1

 

1

 

1

 

1

 

1

 

 ≥ 88

1.44 (0.95–2.18)

 

1.75 (0.99–3.06)

 

1.59 (0.73–3.49)

 

2.30 (0.89–5.99)

 

1.00 (0.42–2.41)

 

0.99 (0.37–2.68)

 

 Per 10 U

1.19 (1.06–1.34)

0.004

1.28 (1.11–1.48)

0.001

1.36 (1.04–2.77)

0.024

1.62 (1.10–2.37)

0.014

0.94 (0.70–1.27)

0.696

0.94 (0.70–1.34)

0.849

Waist-to-hip ratio

 

0.013

 

0.087

 

0.735

 

0.176

 

0.357

 

0.231

 ≤ 0.85

1

 

1

 

1

 

1

 

1

 

1

 

 > 0.85

1.85 (1.14–2.99)

 

1.67 (0.93–3.00)

 

1.14 (0.53–2.44)

 

1.97 (0.74–5.27)

 

1.75 (0.53–5.78)

 

2.27 (0.59–8.71)

 

 Per 0.1 U

1.26 (1.04–1.53)

0.019

1.32 (1.03–1.68)

0.028

1.42 (0.91–2.21)

0.124

1.49 (0.86–2.59)

0.154

1.30 (0.69–2.42)

0.417

1.32 (0.67–2.61)

0.418

Metabolic syndrome (MetS)

 

0.125

 

0.169

 

0.005

 

0.002

 

0.766

 

0.903

 No

1

 

1

 

1

 

1

 

1

 

1

 

 Yes

1.42 (0.91–2.23)

 

1.52 (0.84–2.76)

 

3.45 (1.45–8.22)

 

5.05 (1.80–14.20)

 

1.18 (0.41–3.44)

 

1.08 (0.33–3.51)

 

MetS components

 

0.019

 

0.061

 

0.034

 

0.016

 

0.198

 

0.245

 None

1

 

1

 

1

 

1

 

1

 

1

 

 1–2

3.86 (1.37–10.84)

 

3.68 (1.11–12.22)

 

0.96 (0.29–3.21)

 

0.55 (0.14–2.14)

 

6.99 (0.84–58.08)

 

6.15 (0.73–52.10)

 

 ≥ 3

4.65 (1.59–13.57)

 

4.62 (1.30–16.46)

 

3.03 (0.83–11.03)

 

2.94 (0.75–11.56)

 

5.69 (0.59–54.77)

 

4.72 (0.47–47.87)

 
  1. HR+, hormone receptor, HER2+ human epidermal growth factor receptor-2, TN triple negative.
  2. *Cox proportional hazard ratio (HR) adjusted by terms of: age (≤ 40, 41–60, > 60), center (IRCCS G. Pascale, Policlinico Federico II), cancer stage (I–IIA, IIB, IIIA–IIIC);
  3. **For the entire variable the p-value refers to Wald Test, for numerical variable z-Test p-value was reported.
  4. Significant results are shown in bold.
Back to article page